The United States Patent and Trademark Office (USPTO) has issued patent US12583888B2 to the University of Tartu for novel bi-specific peptides. These peptides are engineered to specifically bind to cancer cells and the extracellular matrix, particularly targeting fibronectin extra domain B (FN-EDB) and tenascin-C C domain (TNC-C). This patent grant signifies the recognition of novel therapeutic compositions and methods for cancer treatment.

While this is a patent grant and not a regulatory rule, companies involved in peptide-based cancer therapeutics, particularly those utilizing fibronectin or tenascin-C binding mechanisms, should be aware of this intellectual property. The patent may impact research and development efforts, licensing opportunities, and potential market exclusivity for similar technologies. No immediate compliance actions are required for regulated entities, but awareness of this granted patent is advisable for strategic planning.